Opinion|Videos|December 3, 2024
Exploring Rebyota for Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Rebyota introduces a diverse array of beneficial bacteria to restore gut microbiota balance, differing from conventional FMT's direct stool transfer.
- It is a standardized, commercially prepared product, ensuring consistent dosing and reducing variability compared to donor-derived FMT.
The panelist discusses how Rebyota is an FDA-approved microbiome therapeutic that delivers standardized, purified intestinal microbiota through enema administration to restore gut microbial diversity and prevent recurrent Clostridioides difficile infection, differing from conventional fecal microbiota transplantation (FMT) in its regulatory status, standardized manufacturing process, and enhanced safety profile due to extensive screening and purification of donor material.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What is the mechanism of action of Rebyota, and how does this therapy differ from conventional FMT?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5